Article History
Received: 9 August 2021
Accepted: 9 August 2021
First Online: 6 September 2021
Disclosure
: Julie Hallet has received speaking honoraria from Ipsen Biopharmaceuticals Canada, Novartis Oncology, and Advanced Accelerator Applications. The remaining authors have no conflicts of interest.